This e-learning course discusses the impact of TRIBE-2, Re-ARRANGE and FOxTROT data in colorectal cancer (CRC) on sequential clinical practice. Key clinical questions will be addressed, including;
- Can we use a flexible dosing approach for regorafenib to improve the safety profile without affecting the efficacy in refractory metastatic colorectal cancer (mCRC)?
- What is the best sequential therapy strategy in mCRC: a classic first and second line regimen or upfront higher regimen followed by the same regimen?
- Is neoadjuvant chemotherapy effective in the treatment of CRC?
This course has been accredited by EACCME® for 1 ECMEC® (as detailed within the Introduction and Objectives below).
The length of treatment for colorectal cancer (CRC) patients in the adjuvant setting is a controversial topic. Recent studies have compared the outcomes for patients receiving adjuvant therapy with FOLFOX or CAPOX for 3 or for 6 months. What should be the recommended length of treatment for CRC patients in the adjuvant setting? Do recent data support a 3-month or 6-month duration? The following e-learning course includes expert opinions on the latest answers to these important questions.
The SHARE 5 Step Communication Framework for Shared Decision-Making in 3rd-Line Treatment of Metastatic Colorectal Cancer (mCRC)
This e-learning demonstrates what you need to explain to your patients requiring 3rd-line treatment of mCRC and how to confidently communicate these messages for an optimal physician-patient interaction.
Ultimately, success is both parties being satisfied with the decision-making process and with the decision that is made.
Experts provide opposing perspectives on the management of later-line CRC on treatment sequencing and flexible dosing of regorafenib.
Note that the views presented do not reflect the Experts’ own opinions but are intended to represent opposing perspectives on the topic of discussion.